Stock Events

Stock Events

Recursion Pharmaceuticals 

$3.50
1369
+$0.16+4.79% Friday 20:00
-$0.00-0.04%Friday 23:59After hours

Statistics

Day High
3.63
Day Low
3.37
52W High
7.18
52W Low
2.77
Volume
22,743,289
Avg. Volume
20,924,330
Mkt Cap
1.88B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.53
-0.43
-0.32
-0.22
Expected EPS
-0.219007
Actual EPS
N/A

Financials

-863.35%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
74.68MRevenue
-644.76MNet Income

Analyst Ratings

7.38Average Price Target
The highest estimate is 10.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RXRX. It's not an investment recommendation.
NVIDIA
362
NVDA
Palantir Technologies
261
PLTR
Tesla
247
TSLA
Microsoft
243
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Schwab U.S. Broad Market
SCHB
Mkt Cap0
Schrodinger operates in computational drug discovery, directly competing with Recursion's AI-driven drug discovery platform.
Illumina
ILMN
Mkt Cap28.82B
Illumina provides genomic sequencing solutions, competing in the broader market of personalized medicine that Recursion targets.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a field that intersects with Recursion's work in genetic-driven drug discovery.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine works on gene editing, competing with Recursion's efforts in leveraging genetics for drug discovery.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another gene editing company, indicating direct competition in the innovative treatment space with Recursion.
Twist Bioscience
TWST
Mkt Cap7.44B
Twist Bioscience synthesizes DNA, competing in the biotech space by enabling research that could overlap with Recursion's drug discovery efforts.
Pacific Biosciences of California
PACB
Mkt Cap357.46M
Pacific Biosciences offers sequencing solutions, indirectly competing by providing essential technology for genetic research like Recursion's.
Bionano Genomics
BNGO
Mkt Cap13.9M
Bionano Genomics focuses on genomic analysis, competing in the genomics space that supports Recursion's drug discovery process.

About

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Show more...
CEO
Najat Khan
Employees
600
Country
United States
ISIN
US75629V1044

Listings

MX
MX
RXRX.MX
XNAS
US
RXRX
BOATS
BOATS
RXRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Recursion Pharmaceuticals stock price today?▼
The current price of RXRX is $3.50 USD — it has increased by +4.79% in the past 24 hours. Watch Recursion Pharmaceuticals stock price performance more closely on the chart.
What is Recursion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Recursion Pharmaceuticals stocks are traded under the ticker RXRX.
Is Recursion Pharmaceuticals stock price growing?▼
RXRX stock has risen by +10.76% compared to the previous week, the month change is a +16.28% rise, over the last year Recursion Pharmaceuticals has showed a -29.15% decrease.
What is Recursion Pharmaceuticals market cap?▼
Today Recursion Pharmaceuticals has the market capitalization of 1.88B
When is the next Recursion Pharmaceuticals earnings date?▼
Recursion Pharmaceuticals is going to release the next earnings report on November 11, 2026.
What were Recursion Pharmaceuticals earnings last quarter?▼
RXRX earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.24 USD resulting in a -4.17% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Recursion Pharmaceuticals revenue for the last year?▼
Recursion Pharmaceuticals revenue for the last year amounts to 74.68M USD.
What is Recursion Pharmaceuticals net income for the last year?▼
RXRX net income for the last year is -644.76M USD.
How many employees does Recursion Pharmaceuticals have?▼
As of August 23, 2026, the company has 600 employees.
In which sector is Recursion Pharmaceuticals located?▼
Recursion Pharmaceuticals operates in the Health & Wellness sector.
When did Recursion Pharmaceuticals complete a stock split?▼
Recursion Pharmaceuticals has not had any recent stock splits.
Where is Recursion Pharmaceuticals headquartered?▼
Recursion Pharmaceuticals is headquartered in SALT LAKE CITY, United States.